Showing 1 - 6 results of 6 for search 'Hiroshi Kagamu', query time: 0.02s Refine Results
  1. 1
    Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutations

    Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutations by Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Ayako Shiono, Yu Miura, Kosuke Hashimoto, Satoshi Yamasaki, Fuyumi Nishihara, Hisao Imai, Kunihiko Kobayashi, Hiroshi Kagamu

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer

    Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer by Satoshi Endo, Hisao Imai, Atsuto Mouri, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Junichi Nakagawa, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    A Real‐Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune‐Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab

    A Real‐Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune‐Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolum... by Atsuto Mouri, Hisao Imai, Satoshi Endo, Junichi Nakagawa, Kasumi Tsukamoto, Yuhei Kurata, Ou Yamaguchi, Kenji Masaki, Kosuke Hashimoto, Ayako Shiono, Yu Miura, Kunihiko Kobayashi, Kyoichi Kaira, Hiroshi Kagamu

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study

    Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observati... by Yuhei Kurata, Atsuto Mouri, Hisao Imai, Satoshi Endo, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Junichi Nakagawa, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events

    Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events by Yu Miura, Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Ayako Shiono, Kosuke Hashimoto, Fuyumi Nishihara, Shun Shinomiya, Tomoe Akagami, Yoshitake Murayama, Takanori Abe, Shin‐ei Noda, Shingo Kato, Kunihiko Kobayashi, Hiroshi Kagamu

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study

    Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study by Ayako Shiono, Hisao Imai, Kyoichi Kaira, Takanori Abe, Yuki Sato, Ken Yamamoto, Hiroki Watanabe, Yuko Tsuchiya‐Kawano, Akihiro Tamiya, Takashi Osaki, Noriko Yanagitani, Shigeru Tanzawa, Toshiyuki Sumi, Kohei Yoshimine, Yohei Matsui, Satoshi Endo, Kazuhiko Shibata, Shinnosuke Takemoto, Yosuke Miura, Yoshiaki Nagai, Junichi Nakagawa, Takeshi Tsuda, Hiroshi Kagamu

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: